# Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV

> **NCT04437017** · PHASE3 · COMPLETED · sponsor: **Fifth Affiliated Hospital, Sun Yat-Sen University** · enrollment: 557 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Olanzapine+NK-1 RA+5-HT3 RA
- **DRUG:** Dexamethasone+NK-1 RA+5-HT3 RA

## Key facts

- **NCT ID:** NCT04437017
- **Lead sponsor:** Fifth Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-03
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 557 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04437017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04437017, "Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04437017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*